Basecamp Research Raises $140M Series C to Train New EDEN Models

Basecamp Research, a London-based developer of AI-designed medicines, announced a $140 million Series C financing on September 23, 2026. The round was led by S32, with participation from Anthropic’s Anthology Fund and NVIDIA, and will fund training of a new generation of the company’s EDEN models and advancement of its AI-designed therapeutics pipeline toward clinical development.

Investor Syndicate and Board Appointment

The oversubscribed round also drew Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Additional investment came from senior leaders across pharma, biotech and global industry, including André Hoffmann, Vice-Chairman of Roche. Hoffmann described personalised, AI-designed therapeutics as the next transformation of a biotechnology revolution that began fifty years ago, and said Basecamp Research has built the platform to deliver it.

Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, joins Basecamp Research’s Board of Directors. Conrad said the ability to combine AI, biological data and scientific insight could transform how disease is understood and medicines are discovered, and he described the company as building an important technology platform at the center of that opportunity.

“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” said Glen Gowers, co-founder and CEO of Basecamp Research. He said AI-based approaches promise to change what is possible for patients who currently have few alternatives, and that the funding moves the technology closer to those patients.

Use of Proceeds and the In Vivo Cell Therapy Platform

Beyond model training and pipeline advancement, the company said the financing will expand its pharmaceutical partnerships. To support that effort, Basecamp appointed Richard Pearce, formerly of Biogen, as Chief Business Officer.

Basecamp is applying EDEN, its biological foundation model, to in vivo cell therapy, an approach that reprograms a patient’s cells inside the body. The company characterizes current cell therapies as constrained in the complexity of what they can deliver and as dependent on manufacturing that costs hundreds of thousands of dollars per patient. Its platform combines EDEN’s design of long, complex DNA sequences with large serine recombinases intended to integrate those sequences into the genome. Basecamp says the goal is cell therapies that are more sophisticated and customisable yet simpler to administer, with potential application against cancer and autoimmune disease. The company said it has demonstrated strong preclinical results across multiple modalities and disease areas.

The Trillion Gene Atlas and EDEN Models

At the center of the platform is the Trillion Gene Atlas, which the company describes as the world’s largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents.

Basecamp says the EDEN models trained on this data recognize patterns across a broad range of previously unseen biology and are built to understand how DNA works across all of life rather than to perform a single scientific task. According to the company, the models can produce potential therapeutic candidates directly from disease information, an approach it says was demonstrated through its collaboration with Anthropic on Claude Science, and their capabilities include designing cell and gene therapies, enzymes and peptides. On its website, the company describes EDEN as a 28B-parameter model and states that its dataset holds over 100 billion novel genes at over 100T tokens, with therapeutic platforms spanning gene insertion, gene editing and peptide design advancing through preclinical development.

Prior 2026 Milestones

Basecamp launched the Trillion Gene Atlas on March 18, 2026, at SXSW in Austin and NVIDIA’s GTC conference in San Jose, setting a goal of expanding known evolutionary genetic diversity 100-fold by collecting genomic data from more than 100 million species across thousands of sites. The company said the EDEN foundation models were first released in January 2026 and trained entirely on BaseData, a proprietary genomic database it describes as more than ten times larger than all public resources combined, spanning 10 billion genes new to science across 1 million newly discovered species. Basecamp reported that in wet-lab validation, EDEN showed zero-shot activity in primary human T-cells, generated hits across multiple frontier modalities including what it calls AI-Programmable Gene Insertion, a technique for inserting healthy genes, and achieved a 97% hit rate for designed antimicrobial peptides against priority pathogens.

On June 30, 2026, the company brought EDEN’s antibiotic design and vaccine target prediction models to Claude, including Claude Science, Anthropic’s AI workbench for life sciences research. The capability is offered through Anthropic’s connectors directory in Claude.ai, Claude Desktop, Claude Mobile, Claude Code, Cowork and Claude Science. Basecamp reported that in a collaboration with University of Pennsylvania researchers led by César de la Fuente, 97% of EDEN-designed antibiotic peptides proved active against World Health Organisation priority pathogens in laboratory testing. A candidate designated EDEN-7 showed efficacy in the same range as a last-line antibiotic in mice infected with multidrug-resistant Acinetobacter baumannii, despite being generated without subsequent optimization or iterative engineering, the company said.

Basecamp Research is headquartered in London, with offices and labs in Cambridge, Massachusetts.